Prosztatarák: vizsgálatok itt: Törökország
13 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Ankara, Atakum, Istanbul, Izmir, Seyhan
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00 - 3. fázisTaking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Adana, Ankara, Istanbul, Samsun
- Életkor
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - 3. fázisTaking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Adana, Ankara, Istanbul, Izmir
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - 3. fázisTaking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Adana, Ankara, Istanbul, Izmir, Samsun
- Életkor
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - 3. fázisTaking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Ankara, Istanbul
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 3. fázisTaking peopleSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Adana, Ankara, Cordaleo, Istanbul, Izmir
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Ankara, Cordaleo, Diyarbakır, Istanbul, Izmir, Şahinbey, Sakarya, Seyhan
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisTaking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Ankara, Diyarbakır, Edirne, Izmir, Kadıköy
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Adana, Ankara, Istanbul, Rize
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - 1/2. fázisTaking peopleTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Where
- Ankara
- Életkor
- 18 év and over
- People
- 181 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Ankara, Cordaleo, Edirne, Kadıkoy/Istanbul, Konya, Pamukkale, Samsun
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 3. fázisTaking peopleThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Where
- Ankara, Istanbul
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- Telix Pharmaceuticals (Innovations) Pty Limited
See details and how to joinNCT06520345 - 1. fázisTaking peopleStudy With [225Ac]Ac-FL-020 in mCRPC Participants
- Where
- Ankara
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Full-Life Technologies UK Limited
See details and how to joinNCT06492122